Cover image for Vol. 122 Issue 11

Early View (Online Version of Record published before inclusion in an issue)

Edited By: Fadlo R. Khuri, MD

Impact Factor: 5.068

ISI Journal Citation Reports © Ranking: 2014: 32/211 (Oncology)

Online ISSN: 1097-0142

Associated Title(s): Cancer Cytopathology, CA: A Cancer Journal for Clinicians

  1. Original Articles

    1. Discipline

      Disparities Research
      Racial and ethnic differences in patient navigation: Results from the Patient Navigation Research Program

      Naomi Y. Ko, Frederick R. Snyder, Peter C. Raich, Electra D. Paskett, Donald J. Dudley, Ji-Hyun Lee, Paul H. Levine and Karen M. Freund

      Version of Record online: 26 MAY 2016 | DOI: 10.1002/cncr.30109

      • image

      The current study explores whether patient navigation reduces racial and ethnic differences in the time to diagnostic resolution of a cancer screening abnormality. The study demonstrates that patient navigation significantly reduces the median time to diagnostic resolution in black participants, although the reduction does not appear to entirely eliminate disparities between this and other racial and ethnic groups.

    2. Disease Site

      Genitourinary Disease
      Sex disparities in use of chemotherapy and survival in patients with advanced bladder cancer

      Tracy L. Rose, Allison M. Deal, Matthew E. Nielsen, Angela B. Smith and Matthew I. Milowsky

      Version of Record online: 25 MAY 2016 | DOI: 10.1002/cncr.30029

      • image

      Women are less likely than men to receive systemic chemotherapy for advanced bladder cancer, and this difference may partially account for the poorer overall survival observed in women. However, overall survival remains lower in women independent of chemotherapy use. See also pages 000-000.

  2. Editorial

    1. Mind the gap: What is driving the survival disparity between the sexes in bladder cancer?

      Lauren C. Harshman

      Version of Record online: 25 MAY 2016 | DOI: 10.1002/cncr.30027

      Precis Bladder cancer is well known to preferentially afflict men. However, women are significantly more likely to die of the disease even when corrected for stage, tumor characteristics, and age. In this issue of Cancer, Rose and colleagues highlight concerning disparities in bladder cancer treatment and outcomes between the sexes.

      See also pages 000–000.

  3. Original Articles

    1. Disease Site

      Genitourinary Disease
      Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer

      Joshua A. Halpern, Art Sedrakyan, Wei-Chun Hsu, Jialin Mao, Timothy J. Daskivich, Paul L. Nguyen, Encouse B. Golden, Josephine Kang and Jim C. Hu

      Version of Record online: 25 MAY 2016 | DOI: 10.1002/cncr.30101

      • image
      • image

      The use of stereotactic body radiotherapy (SBRT) and proton beam therapy for the treatment of patients with localized prostate cancer in the United States has increased over time. Despite men of lower stage undergoing SBRT, SBRT appears to be associated with greater toxicity but lower health care costs compared with other radiotherapies.

    2. Breast Disease
      You have full text access to this OnlineOpen article
      An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy

      Christina M. Dieli-Conwright, Louise Wong, Sarah Waliany, Leslie Bernstein, Behrouz Salehian and Joanne E. Mortimer

      Version of Record online: 24 MAY 2016 | DOI: 10.1002/cncr.30104

      Patients with breast cancer who receive (neo)adjuvant chemotherapy experience an impaired metabolic presentation as noted by worsened components of metabolic syndrome, anthropometrics, and biomarkers of glucose metabolism. Lifestyle interventions such as diet and exercise may be preventive approaches for use during chemotherapy to reduce the onset of metabolic syndrome in patients with breast cancer.

    3. Gastrointestinal Disease
      Predicting advanced neoplasia at colonoscopy in a diverse population with the National Cancer Institute colorectal cancer risk-assessment tool

      Uri Ladabaum, Ashley Patel, Ajitha Mannalithara, Vandana Sundaram, Aya Mitani and Manisha Desai

      Version of Record online: 24 MAY 2016 | DOI: 10.1002/cncr.30096

      • image
      • image
      • image
      • image

      The National Cancer Institute colorectal cancer risk-assessment tool, which was designed to predict future colorectal cancer risk, displays modest discriminatory accuracy in predicting advanced neoplasia at screening colonoscopy in a diverse population. This tool may aid shared decision-making in clinical practice.

    4. Discipline

      Pediatric Oncology
      Parental preparedness for late effects and long-term quality of life in survivors of childhood cancer

      Katie A. Greenzang, Angel M. Cronin and Jennifer W. Mack

      Version of Record online: 24 MAY 2016 | DOI: 10.1002/cncr.30092

      • image
      • image

      The parents of children with cancer believe themselves to be prepared to manage their child's cancer treatment, but they feel less prepared for survivorship. High-quality communication with providers may help parents to feel more prepared for their child's life after cancer therapy.

    5. Diagnostic Imaging
      Second-opinion interpretations of neuroimaging studies by oncologic neuroradiologists can help reduce errors in cancer care

      Vaios Hatzoglou, Antonio M. Omuro, Sofia Haque, Yasmin Khakoo, Ian Ganly, Jung Hun Oh, Amita Shukla-Dave, Robin Fatovic, Joshua Gaal and Andrei I. Holodny

      Version of Record online: 24 MAY 2016 | DOI: 10.1002/cncr.30083

      • image
      • image

      Delivering the highest quality of cancer care is an important issue and must continue to be emphasized. Second-opinion interpretations of neuroimaging studies by subspecialized oncologic neuroradiologists reduce error and optimize the care of cancer patients.

    6. Radiation Oncology
      PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer

      Andrew J. McPartlin, Rachel Glicksman, Melania Pintilie, Debbie Tsuji, Gary Mok, Andrew Bayley, Peter Chung, Robert G. Bristow, Mary K. Gospodarowicz, Charles N. Catton, Michael Milosevic and Padraig R. Warde

      Version of Record online: 24 MAY 2016 | DOI: 10.1002/cncr.30093

      • image
      • image
      • image
      • image

      The PMH 9907 trial was a randomized study assessing the outcome of dose-escalated external-beam radiotherapy with or without 5 months neoadjuvant and concurrent bicalutamide 150 mg once daily for 252 patients with localized prostate cancer. After a median follow-up of 9.1 years, a nonsignificant 7% difference in the biochemical failure rate is reported in favor of combination therapy.

    7. Outcomes Research
      Early impact of Medicare accountable care organizations on cancer surgery outcomes

      Lindsey A. Herrel, Edward C. Norton, Scott R. Hawken, Zaojun Ye, Brent K. Hollenbeck and David C. Miller

      Version of Record online: 24 MAY 2016 | DOI: 10.1002/cncr.30111

      • image

      Early hospital participation in the accountable care organization program of the Medicare Shared Savings Program is not associated with greater reductions in adverse perioperative outcomes for patients undergoing a major cancer surgery in comparison with control hospitals. The longitudinal improvements in perioperative outcomes identified during the study interval may reflect the impact of concurrent policies more directly applicable to surgical patients.

    8. Psychosocial Oncology
      Young adult female cancer survivors' unmet information needs and reproductive concerns contribute to decisional conflict regarding posttreatment fertility preservation

      Catherine Benedict, Bridgette Thom, Danielle N. Friedman, Debbie Diotallevi, Elaine M. Pottenger, Nirupa J. Raghunathan and Joanne F. Kelvin

      Version of Record online: 23 MAY 2016 | DOI: 10.1002/cncr.29917

      • image

      Young adult female cancer survivors who maintain their reproductive ability after gonadotoxic treatments report decisional conflict when prompted to consider future fertility preservation. The results of the current study indicate that greater levels of unmet information needs and reproductive concern contribute to increased conflict. Survivorship care should include comprehensive reproductive health counseling and resources to support survivors in making informed, values-based decisions regarding their reproductive options.

    9. Disease Site

      Gastrointestinal Disease
      Colorectal cancer screening: Estimated future colonoscopy need and current volume and capacity

      Djenaba A. Joseph, Reinier G. S. Meester, Ann G. Zauber, Diane L. Manninen, Linda Winges, Fred B. Dong, Brandy Peaker and Marjolein van Ballegooijen

      Version of Record online: 20 MAY 2016 | DOI: 10.1002/cncr.30070

      • image
      • image
      • image

      There is sufficient colonoscopy capacity to screen 80% of the eligible US population with fecal immunochemical testing, colonoscopy, or a mix of tests.

    10. Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers

      Zachary S. Morris, Sandeep Saha, William J. Magnuson, Brett A. Morris, Jenna F. Borkenhagen, Alisa Ching, Gayle Hirose, Vanesa McMurry, David M. Francis, Paul M. Harari, Rick Chappell, Stuart Tsuji and Mark A. Ritter

      Version of Record online: 20 MAY 2016 | DOI: 10.1002/cncr.30079

      • image
      • image

      The incidental use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among rectal cancer patients receiving neoadjuvant radiotherapy is associated with an increased rate of pathological complete response. This finding is verified in a second independent database, and a multivariate aggregate analysis shows that the use of these medications is a strong predictor of a pathologic complete response.

    11. Hematologic Malignancies
      Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma

      Yago Nieto, Benigno C. Valdez, Peter F. Thall, Roy B. Jones, Wei Wei, Alan Myers, Chitra Hosing, Sairah Ahmed, Uday Popat, Elizabeth J. Shpall, Muzaffar Qazilbash, Alison Gulbis, Paolo Anderlini, Nina Shah, Qaiser Bashir, Amin Alousi, Yasuhiro Oki, Michelle Fanale, Bouthaina Dabaja, Chelsea Pinnix, Richard Champlin and Borje S. Andersson

      Version of Record online: 20 MAY 2016 | DOI: 10.1002/cncr.30100

      • image
      • image

      With the objective of developing more active high-dose chemotherapy for patients with refractory or high-risk relapsed lymphomas, infusional gemcitabine/busulfan/melphalan is combined with vorinostat and azacitidine (which enhanced antitumor activity in preclinical work). This clinical trial demonstrates that double epigenetic modulation of high-dose chemotherapy is safe and highly active in patients with refractory lymphomas.

    12. Discipline

      Radiation Oncology
      Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT)

      Anthony C. Wong, Sydeaka P. Watson, Sean P. Pitroda, Christina H. Son, Lauren C. Das, Melinda E. Stack, Abhineet Uppal, Go Oshima, Nikolai N. Khodarev, Joseph K. Salama, Ralph R. Weichselbaum and Steven J. Chmura

      Version of Record online: 20 MAY 2016 | DOI: 10.1002/cncr.30058

      • image
      • image
      • image

      Predictors of outcomes in oligometastatic patients treated with ablative stereotactic radiotherapy (SBRT) are poorly defined. We report that breast cancer histology and slow progression are associated with longer survival in this long-term update of a prospective SBRT dose escalation trial, and we propose a microRNA classifier that may help select oligometastatic patients with better prognosis.

    13. Psychosocial Oncology
      Peer-counseling for women newly diagnosed with breast cancer: A randomized community/research collaboration trial

      Janine Giese-Davis, Caroline Bliss-Isberg, Lynne Wittenberg, Jennifer White, Path Star, Lihong Zhong, Matthew J. Cordova, Debra Houston and David Spiegel

      Version of Record online: 19 MAY 2016 | DOI: 10.1002/cncr.30036

      • image
      • image

      The findings of the current randomized controlled trial indicate that, compared with controls, a peer-counseling intervention significantly improves quality of life and maintains marital adjustment in patients with breast cancer. Having a peer counselor may prevent or improve psychosocial morbidity after diagnosis.

  4. Correspondence

    1. Reply to the association between religion/spirituality and mental health in cancer

      John M. Salsman, James E. Pustejovsky, Crystal L. Park, Allen C. Sherman, Thomas V. Merluzzi, Suzanne C. Danhauer, Heather S.L. Jim and George Fitchett

      Version of Record online: 19 MAY 2016 | DOI: 10.1002/cncr.30019

  5. Original Articles

    1. Discipline

      Clinical Trials
      A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies

      Rana R. McKay, Guillermo De Velasco, Lillian Werner, Joaquim Bellmunt, Lauren Harshman, Christopher Sweeney, Jonathan E. Rosenberg, Michelle Hirsch, Sabina Signoretti, Eliezer M. Van Allen, Meghara Walsh, Ulka Vaishampayan, David F. McDermott and Toni K. Choueiri

      Version of Record online: 19 MAY 2016 | DOI: 10.1002/cncr.30056

      • image
      • image

      The phosphatidylinositol-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is dysregulated in patients with metastatic renal cell carcinoma (mRCC), and targeting this pathway, in addition to the vascular endothelial growth factor (VEGF) pathway, is a potential therapeutic strategy in the management of RCC. Buparlisib at a dose of 80 mg/day with bevacizumab appears to be a tolerable regimen with preliminary activity in patients with vascular endothelial growth factor-refractory mRCC.

  6. Review Articles

    1. Role of isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan in locally advanced extremity soft tissue sarcoma

      Jens Jakob and Peter Hohenberger

      Version of Record online: 19 MAY 2016 | DOI: 10.1002/cncr.29991

      • image
      • image
      • image

      Isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan is a highly effective regional treatment for locally advanced soft tissue sarcoma. This review critically discusses the indication for isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan.